Investor Relations

2018 Press Releases

RSS RSS Feeds | E-mail Alerts Receive E-mail Alerts
Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
08/08/18Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/01/18Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8Printer Friendly Version
06/27/18CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103Printer Friendly Version
06/27/18Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103Printer Friendly Version
06/14/18Foamix Pharmaceuticals to Participate in the Cantor Dermatology & Aesthetics SummitPrinter Friendly Version
05/08/18Foamix Reports First Quarter 2018 Financial Results and Provides Corporate UpdatePrinter Friendly Version
05/07/18Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101Printer Friendly Version
04/24/18Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for May 9Printer Friendly Version
04/16/18Foamix Announces $16 Million Investment by OrbiMedPrinter Friendly Version
03/08/18Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2018Printer Friendly Version
03/06/18Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care ConferencePrinter Friendly Version
02/28/18Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/13/18Foamix Pharmaceuticals Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call & Webcast Scheduled for February 28Printer Friendly Version
01/04/18Foamix Announces Positive Results from Phase 3 Open-Label Safety Extension Evaluating FMX-101 Topical Minocycline Foam for Treatment up to 1 YearPrinter Friendly Version
01/03/18Foamix Names Mr. David Domzalski as a Member of the Board of Foamix PharmaceuticalsPrinter Friendly Version